Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 9/20 | 0.59 |
| ▸ | HTT | P42858 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075620 | 0.93 | PKM (0.60) | SMN1; SMN2PKMHPGDTAS2R14TSHR | |
| SCHEMBL2594417 | 0.86 | PKM (0.69) | PKMALDH1A1KMT2AMEN1GAA | |
| SCHEMBL10076055 | 0.85 | PKM (0.50) | SMN1; SMN2PKMHPGDTAS2R14TSHR | |
| SCHEMBL10075472 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2PKMALDH1A1HTTKMT2A | |
| SCHEMBL10075480 | 0.84 | MAPT (0.59) | SMN1; SMN2PKMALDH1A1LMNAHTT | |
| SCHEMBL10075476 | 0.84 | PKM (0.56) | SMN1; SMN2PKMALDH1A1KMT2AMEN1 | |
| SCHEMBL10075478 | 0.83 | MAPT (0.64) | PKMHPGDALDH1A1LMNAKMT2A | |
| SCHEMBL10075475 | 0.83 | MAPT (0.53) | PKMTSHRALDH1A1LMNAKMT2A | |
| SCHEMBL10075619 | 0.82 | MAPT (0.62) | PKMTSHRALDH1A1 | |
| SCHEMBL15818506 | 0.81 | PKM (0.58) | SMN1; SMN2PKMALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2655350-B1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012088314-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | SMN1; SMN2 4500/4885PKM 5/4885HPGD 1043/4885 |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | PDK1, PDK2, PCK1 | SMN1; SMN2 3053/4885PKM 7/4885HPGD 1522/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | SMN1; SMN2 3273/4885PKM 9/4885HPGD 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.